| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2022-03-07 02:49:03 UTC |
|---|
| HMDB ID | HMDB0000524 |
|---|
| Secondary Accession Numbers | - HMDB0000655
- HMDB00524
- HMDB00655
|
|---|
| Metabolite Identification |
|---|
| Common Name | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol |
|---|
| Description | 5β-Cholestane-3α,7α,12α,25-tetrol is an intermediate in the bile acid synthetic pathway, and is secreted into the bile and urine following glucuronidation. It does not undergo enterohepatic circulation. In cerebrotendinous xanthomatosis (CTX), a bile acid synthesis disorder caused by sterol 27-hydroxylase (CYP27) deficiency, early intermediates and cholestanol accumulate in a variety of tissues, and glucuronides of 25-hydroxylated bile alcohols are released in bile, blood, and urine (PMID: 11181760 ). Bile acid synthesis from cholesterol is tightly regulated via a feedback mechanism mediated by the farnesoid X receptor (FXR), a nuclear receptor activated by bile acids. Synthesis via the classic pathway is initiated by a series of cholesterol ring modifications and followed by the side chain cleavage. The enhanced cholesterol 7 alpha-hydroxylase (CYP7A1) expression in CYP27 deficiency may be the result of a decreased flux of bile acids and bile alcohols into the liver, while production of FXR-activating 5β-cholestane-3α,7α,12α,25-tetrol is increased (PMID: 15145977 ). |
|---|
| Structure | [H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCCC(C)(C)O InChI=1S/C27H48O4/c1-16(7-6-11-25(2,3)31)19-8-9-20-24-21(15-23(30)27(19,20)5)26(4)12-10-18(28)13-17(26)14-22(24)29/h16-24,28-31H,6-15H2,1-5H3/t16-,17+,18-,19-,20+,21+,22-,23+,24+,26+,27-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 5b-Cholestane-3a,7a,12a,25-tetrol | Generator | | 5Β-cholestane-3α,7α,12α,25-tetrol | Generator | | 5 beta Cholestane-3 alpha,7 alpha,12 alpha,25-tetrol | HMDB | | 5 beta-Cholestane-3 beta,7 alpha,12 alpha,25-tetrol | HMDB | | Cholestane-3,7,12,25-tetrol | HMDB | | (3Α,5β,7α,12α)-cholestane-3,7,12,25-tetrol | HMDB | | 3Α,7α,12α,25-tetrahydroxycoprostane | HMDB | | (3alpha,5beta,7alpha,12alpha)-Cholestane-3,7,12,25-tetrol | HMDB | | 3alpha,7alpha,12alpha,25-Tetrahydroxycoprostane | HMDB | | 5b-Cholestan-3a,7a,12a,25-tetrol | HMDB | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol | Generator |
|
|---|
| Chemical Formula | C27H48O4 |
|---|
| Average Molecular Weight | 436.677 |
|---|
| Monoisotopic Molecular Weight | 436.355260026 |
|---|
| IUPAC Name | (1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-14-[(2R)-6-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane-5,9,16-triol |
|---|
| Traditional Name | (1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-14-[(2R)-6-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane-5,9,16-triol |
|---|
| CAS Registry Number | 18866-87-0 |
|---|
| SMILES | [H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCCC(C)(C)O |
|---|
| InChI Identifier | InChI=1S/C27H48O4/c1-16(7-6-11-25(2,3)31)19-8-9-20-24-21(15-23(30)27(19,20)5)26(4)12-10-18(28)13-17(26)14-22(24)29/h16-24,28-31H,6-15H2,1-5H3/t16-,17+,18-,19-,20+,21+,22-,23+,24+,26+,27-/m1/s1 |
|---|
| InChI Key | NTIXPPFPXLYJCT-RNUSRIHUSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as cholesterols and derivatives. Cholesterols and derivatives are compounds containing a 3-hydroxylated cholestane core. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Cholestane steroids |
|---|
| Direct Parent | Cholesterols and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Cholesterol
- Cholesterol-skeleton
- 25-hydroxysteroid
- 3-hydroxysteroid
- 12-hydroxysteroid
- 7-hydroxysteroid
- Hydroxysteroid
- 3-alpha-hydroxysteroid
- Cyclic alcohol
- Tertiary alcohol
- Secondary alcohol
- Polyol
- Organic oxygen compound
- Alcohol
- Organooxygen compound
- Hydrocarbon derivative
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 6.77 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.6311 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.1 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 71.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3136.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 178.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 225.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 164.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 433.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 778.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 690.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 99.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1120.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 571.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1700.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 399.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 476.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 207.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 285.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 17.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TMS,isomer #1 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C | 3380.4 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TMS,isomer #2 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O | 3471.8 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TMS,isomer #3 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O | 3440.9 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TMS,isomer #4 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O | 3555.3 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TMS,isomer #1 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C | 3483.6 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TMS,isomer #2 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C | 3337.2 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TMS,isomer #3 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C | 3331.6 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TMS,isomer #4 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O | 3560.3 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TMS,isomer #5 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O | 3362.3 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TMS,isomer #6 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O | 3559.9 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TMS,isomer #1 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C | 3481.2 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TMS,isomer #2 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C | 3466.8 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TMS,isomer #3 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C | 3331.1 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TMS,isomer #4 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O | 3513.2 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,4TMS,isomer #1 | C[C@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C | 3483.6 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TBDMS,isomer #1 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 3605.8 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TBDMS,isomer #2 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O | 3692.5 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TBDMS,isomer #3 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O | 3670.7 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,1TBDMS,isomer #4 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O | 3796.7 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TBDMS,isomer #1 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 3930.0 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TBDMS,isomer #2 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 3793.2 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TBDMS,isomer #3 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 3783.5 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TBDMS,isomer #4 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O | 4038.2 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TBDMS,isomer #5 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O | 3822.1 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,2TBDMS,isomer #6 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O | 4020.8 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TBDMS,isomer #1 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 4136.0 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TBDMS,isomer #2 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 4119.9 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TBDMS,isomer #3 | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 3991.5 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,3TBDMS,isomer #4 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O | 4189.8 | Semi standard non polar | 33892256 | | 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol,4TBDMS,isomer #1 | C[C@H](CCCC(C)(C)O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@@]21C)[C@@]1(C)CC[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C[C@H]3O[Si](C)(C)C(C)(C)C | 4334.3 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TMS_4_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol GC-MS (TBDMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 10V, Positive-QTOF | splash10-0uxr-0000900000-ce7599af15d682b569c4 | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 20V, Positive-QTOF | splash10-0udi-1005900000-372cbf89a7b70f683e60 | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 40V, Positive-QTOF | splash10-0f7a-2209200000-de49d287713beec95040 | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 10V, Negative-QTOF | splash10-00kr-0001900000-f8627b8fe61026d323ea | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 20V, Negative-QTOF | splash10-014r-0002900000-e0dbc20b7cbe891c1ef9 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 40V, Negative-QTOF | splash10-0uy0-2017900000-ec2da6f1ebd80a8be486 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 10V, Positive-QTOF | splash10-0uxr-0000900000-3776cbb3f067b3114cea | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 20V, Positive-QTOF | splash10-0uy3-9431700000-e8fb6d533c341214e749 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 40V, Positive-QTOF | splash10-0btc-9531000000-a56819513601843f6933 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 10V, Negative-QTOF | splash10-000i-0000900000-0c413525e4be8a74c95d | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 20V, Negative-QTOF | splash10-000i-0000900000-ac053244f41b05618d02 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5beta-Cholestane-3alpha,7alpha,12alpha,25-tetrol 40V, Negative-QTOF | splash10-001i-0001900000-46fbc2ed078e9f536fdc | 2021-09-23 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Honda A, Salen G, Matsuzaki Y, Batta AK, Xu G, Leitersdorf E, Tint GS, Erickson SK, Tanaka N, Shefer S: Differences in hepatic levels of intermediates in bile acid biosynthesis between Cyp27(-/-) mice and CTX. J Lipid Res. 2001 Feb;42(2):291-300. [PubMed:11181760 ]
- Kosaka D, Hiraoka T, Kohoda T, Kajiyama G, Yamauchi T, Kihira K, Kuramoto T, Hoshita T: Stable isotope dilution assay for 5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrol and 5 beta-cholestane-3 alpha,7 alpha,12 alpha,23,25-pentol in human serum using [26,27-D6] labeled internal standards; a highly accurate approach to the serological diagnosis of cerebrotendinous xanthomatosis. Clin Chim Acta. 1991 May 31;199(1):83-9. [PubMed:1934504 ]
- Dayal B, Ertel NH, Padia J, Rapole KR, Salen G: 7 beta-hydroxy bile alcohols: facile synthesis and 2D 1H NMR studies of 5 beta-cholestane-3 alpha, 7 beta, 12 alpha, 25-tetrol. Steroids. 1997 May;62(5):409-14. [PubMed:9178427 ]
- Dayal B, Greeley DN, Williams TH, Tint GS, Salen G: Stereospecific synthesis of 3 beta-hydroxylated bile alcohols. J Lipid Res. 1984 Jun;25(6):646-50. [PubMed:6747468 ]
- Cronholm T: Excretion of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha, 26-tetrol and corticosterone metabolites in rat bile. Studies on the role of alcohol dehydrogenase in steroid metabolism. J Steroid Biochem. 1984 Jun;20(6A):1321-5. [PubMed:6379302 ]
- Dayal B, Salen G, Padia J, Shefer S, Tint GS, Sasso G, Williams TH: Bile alcohol glucuronides: regioselective O-glucuronidation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrol and 24-nor-5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrol. Carbohydr Res. 1993 Feb 24;240:133-42. [PubMed:8458007 ]
- Nishimaki-Mogami T, Une M, Fujino T, Sato Y, Tamehiro N, Kawahara Y, Shudo K, Inoue K: Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor. J Lipid Res. 2004 Aug;45(8):1538-45. Epub 2004 May 16. [PubMed:15145977 ]
|
|---|